Briefing
Analytical evaluation of the clonoSEQ Assay for establishing measurable residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
The paper reports analytical sensitivity and specificity of the clonoSEQ next-generation sequencing assay for measurable residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
- Design: Evidence level 3
- Assay: clonoSEQ